Last reviewed · How we verify
TP-102
At a glance
| Generic name | TP-102 |
|---|---|
| Sponsor | Technophage, SA |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection (PHASE2)
- Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TP-102 CI brief — competitive landscape report
- TP-102 updates RSS · CI watch RSS
- Technophage, SA portfolio CI